Barclays raised the firm’s price target on Corebridge (CRBG) to $45 from $38 and keeps an Overweight rating on the shares after the company announced a variable annuity reinsurance transaction on $51bn of assets under management with Venerable. The deal would fully eliminate Corebridge’s exposure to individual VA products, notes the analyst, who thinks the company’s VA exposure has been a drag on valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBG:
- Corebridge enters $2.8B reinsurance agreement with CS Life Re
- Corebridge Financial Announces Major Reinsurance Transaction
- Corebridge Financial Elects Directors at Annual Meeting
- Corebridge participates in a conference call with JPMorgan
- Corebridge price target raised to $37 from $32 at Morgan Stanley